OBJECTIVE: In multiple sclerosis (MS), using simultaneous magnetic resonance-positron emission tomography (MR-PET) imaging with 11 C-PBR28, we quantified expression of the 18kDa translocator protein (TSPO), a marker of activated microglia/macrophages, in cortex, cortical lesions, deep gray matter (GM), white matter (WM) lesions, and normal-appearing WM (NAWM) to investigate the in vivo pathological and clinical relevance of neuroinflammation. METHODS: Fifteen secondary-progressive MS (SPMS) patients, 12 relapsing-remitting MS (RRMS) patients, and 14 matched healthy controls underwent 11 C-PBR28 MR-PET. MS subjects underwent 7T T2*-weighted imaging for cortical lesion segmentation, and neurological and cognitive evaluation. 11 C-PBR28 binding was measured using normalized 60- to 90-minute standardized uptake values and volume of distribution ratios. RESULTS: Relative to controls, MS subjects exhibited abnormally high 11 C-PBR28 binding across the brain, the greatest increases being in cortex and cortical lesions, thalamus, hippocampus, and NAWM. MS WM lesions showed relatively modest TSPO increases. With the exception of cortical lesions, where TSPO expression was similar, 11 C-PBR28 uptake across the brain was greater in SPMS than in RRMS. In MS, increased 11 C-PBR28 binding in cortex, deep GM, and NAWM correlated with neurological disability and impaired cognitive performance; cortical thinning correlated with increased thalamic TSPO levels. INTERPRETATION: In MS, neuroinflammation is present in the cortex, cortical lesions, deep GM, and NAWM, is closely linked to poor clinical outcome, and is at least partly linked to neurodegeneration. Distinct inflammatory-mediated factors may underlie accumulation of cortical and WM lesions. Quantification of TSPO levels in MS could prove to be a sensitive tool for evaluating in vivo the inflammatory component of GM pathology, particularly in cortical lesions. Ann Neurol 2016;80:776-790.
OBJECTIVE: In multiple sclerosis (MS), using simultaneous magnetic resonance-positron emission tomography (MR-PET) imaging with 11 C-PBR28, we quantified expression of the 18kDa translocator protein (TSPO), a marker of activated microglia/macrophages, in cortex, cortical lesions, deep gray matter (GM), white matter (WM) lesions, and normal-appearing WM (NAWM) to investigate the in vivo pathological and clinical relevance of neuroinflammation. METHODS: Fifteen secondary-progressive MS (SPMS) patients, 12 relapsing-remitting MS (RRMS) patients, and 14 matched healthy controls underwent 11 C-PBR28 MR-PET. MS subjects underwent 7T T2*-weighted imaging for cortical lesion segmentation, and neurological and cognitive evaluation. 11 C-PBR28 binding was measured using normalized 60- to 90-minute standardized uptake values and volume of distribution ratios. RESULTS: Relative to controls, MS subjects exhibited abnormally high 11 C-PBR28 binding across the brain, the greatest increases being in cortex and cortical lesions, thalamus, hippocampus, and NAWM. MS WM lesions showed relatively modest TSPO increases. With the exception of cortical lesions, where TSPO expression was similar, 11 C-PBR28 uptake across the brain was greater in SPMS than in RRMS. In MS, increased 11 C-PBR28 binding in cortex, deep GM, and NAWM correlated with neurological disability and impaired cognitive performance; cortical thinning correlated with increased thalamic TSPO levels. INTERPRETATION: In MS, neuroinflammation is present in the cortex, cortical lesions, deep GM, and NAWM, is closely linked to poor clinical outcome, and is at least partly linked to neurodegeneration. Distinct inflammatory-mediated factors may underlie accumulation of cortical and WM lesions. Quantification of TSPO levels in MS could prove to be a sensitive tool for evaluating in vivo the inflammatory component of GM pathology, particularly in cortical lesions. Ann Neurol 2016;80:776-790.
Authors: Jonas Hannestad; Jean-Dominique Gallezot; Thomas Schafbauer; Keunpoong Lim; Tracy Kloczynski; Evan D Morris; Richard E Carson; Yu-Shin Ding; Kelly P Cosgrove Journal: Neuroimage Date: 2012-07-06 Impact factor: 6.556
Authors: Ciprian Catana; Andre van der Kouwe; Thomas Benner; Christian J Michel; Michael Hamm; Matthias Fenchel; Bruce Fischl; Bruce Rosen; Matthias Schmand; A Gregory Sorensen Journal: J Nucl Med Date: 2010-09 Impact factor: 10.057
Authors: Eero Rissanen; Jouni Tuisku; Johanna Rokka; Teemu Paavilainen; Riitta Parkkola; Juha O Rinne; Laura Airas Journal: J Nucl Med Date: 2014-04-07 Impact factor: 10.057
Authors: Douglas N Greve; Claus Svarer; Patrick M Fisher; Ling Feng; Adam E Hansen; William Baare; Bruce Rosen; Bruce Fischl; Gitte M Knudsen Journal: Neuroimage Date: 2013-12-19 Impact factor: 6.556
Authors: Alessandro Colasanti; Qi Guo; Paolo Giannetti; Matthew B Wall; Rexford D Newbould; Courtney Bishop; Mayca Onega; Richard Nicholas; Olga Ciccarelli; Paolo A Muraro; Omar Malik; David R Owen; Allan H Young; Roger N Gunn; Paola Piccini; Paul M Matthews; Eugenii A Rabiner Journal: Biol Psychiatry Date: 2015-12-05 Impact factor: 13.382
Authors: Marios Politis; Paolo Giannetti; Paul Su; Federico Turkheimer; Shiva Keihaninejad; Kit Wu; Adam Waldman; Omar Malik; Paul M Matthews; Richard Reynolds; Richard Nicholas; Paola Piccini Journal: Neurology Date: 2012-07-03 Impact factor: 9.910
Authors: Valeria T Barletta; Elena Herranz; Costantina A Treaba; Russell Ouellette; Ambica Mehndiratta; Marco L Loggia; Eric C Klawiter; Carolina Ionete; Sloane A Jacob; Caterina Mainero Journal: Mult Scler Date: 2019-04-11 Impact factor: 6.312
Authors: Hong Jiang; Giovana Rosa Gameiro; Yi Liu; Ying Lin; Jeffrey Hernandez; Yuqing Deng; Giovanni Gregori; Silvia Delgado; Jianhua Wang Journal: Am J Ophthalmol Date: 2020-01-08 Impact factor: 5.258
Authors: Carmen Tur; Marcello Moccia; Frederik Barkhof; Jeremy Chataway; Jaume Sastre-Garriga; Alan J Thompson; Olga Ciccarelli Journal: Nat Rev Neurol Date: 2018-01-12 Impact factor: 42.937